Payment overview · 2025
General Payments
$936.04
52 reported records · 22 companies
Healthcare provider profile · identity verified
Benjamin P Lyon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GEORGETOWN, KY · NPI 1669471645
Verified facts
What the public records show
CMS Open Payments records show Benjamin P Lyon, M.D. received $936.04 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.85 | 15.8% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $79.16 | 8.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.74 | 8.4% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $68.48 | 7.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.78 | 6.6% | 2 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $51.53 | 5.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $49.04 | 5.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.62 | 5.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.34 | 4.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.99 | 4.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.87 | 3.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.13 | 3.5% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.47 | 3.3% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $29.57 | 3.2% | 2 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $27.00 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.85 | 2.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.40 | 2.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.09 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.38 | 1.8% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.98 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.93 | 1.6% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.84 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $936.04 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $147.85 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $84.85 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $79.16 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $78.74 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $68.48 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $61.78 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $59.47 | 3 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $51.53 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.04 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $43.34 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.99 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.13 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.47 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 169 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
169 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 619 | 186 |
| Atorvastatin Calcium | Atorvastatin Calcium | 594 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 583 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 343 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 318 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 307 | 92 |
| Losartan Potassium | Losartan Potassium | 286 | 91 |
| Lisinopril | Lisinopril | 281 | 74 |
| Gabapentin | Gabapentin | 264 | 77 |
| Simvastatin | Simvastatin | 259 | 71 |
| Meloxicam | Meloxicam | 212 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 61 |
| Alprazolam | Alprazolam | 201 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 55 |
| Furosemide | Furosemide | 193 | 64 |
| Doxazosin Mesylate | Doxazosin Mesylate | 174 | 46 |
| Glimepiride | Glimepiride | 171 | 50 |
| Potassium Chloride | Potassium Chloride | 171 | 51 |
| Eliquis | Apixaban | 169 | 39 |
| Metformin Hcl Er | Metformin Hcl | 167 | 46 |
| Tramadol Hcl | Tramadol Hcl | 167 | 43 |
| Methylprednisolone | Methylprednisolone | 163 | 133 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 46 |
| Metformin Hcl | Metformin Hcl | 142 | 49 |
| Ozempic | Semaglutide | 140 | 20 |
| Temazepam | Temazepam | 140 | 33 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 137 | 107 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 135 | 34 |
| Celecoxib | Celecoxib | 134 | 33 |
| Prednisone | Prednisone | 131 | 68 |
| Trazodone Hcl | Trazodone Hcl | 130 | 35 |
| Sertraline Hcl | Sertraline Hcl | 129 | 39 |
| Montelukast Sodium | Montelukast Sodium | 119 | 34 |
| Bupropion Xl | Bupropion Hcl | 110 | 39 |
| Telmisartan | Telmisartan | 107 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 41 |
| Allopurinol | Allopurinol | 97 | 31 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 97 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 97 | 46 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 97 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 31 |
| Atenolol | Atenolol | 95 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 29 |
| Carvedilol | Carvedilol | 93 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 24 |
| Clonazepam | Clonazepam | 90 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 87 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 47 |
| Jardiance | Empagliflozin | 83 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 78 | 62 |
| Nebivolol Hcl | Nebivolol Hcl | 77 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 27 |
| Pregabalin | Pregabalin | 74 | 17 |
| Fluconazole | Fluconazole | 73 | 31 |
| Warfarin Sodium | Warfarin Sodium | 72 | 15 |
| Levofloxacin | Levofloxacin | 69 | 58 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 48 |
| Methocarbamol | Methocarbamol | 61 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | 22 |
| Trulicity | Dulaglutide | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 15 |
| Valsartan | Valsartan | 51 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 14 |
| Cefdinir | Cefdinir | 49 | 41 |
| Finasteride | Finasteride | 49 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 16 |
| Irbesartan | Irbesartan | 47 | 13 |
| Spironolactone | Spironolactone | 46 | 16 |
| Donepezil Hcl | Donepezil Hcl | 45 | 14 |
| Estradiol | Estradiol | 44 | 12 |
| Glipizide | Glipizide | 44 | 17 |
| Diazepam | Diazepam | 42 | 15 |
| Famotidine | Famotidine | 42 | 14 |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Bumetanide | Bumetanide | 40 | 16 |
| Cephalexin | Cephalexin | 40 | 29 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Acyclovir | Acyclovir | 36 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 32 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Testosterone | Testosterone | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Treximet | Sumatriptan Succ/Naproxen Sod | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $936.04 · 52 records | ABBVIE INC. | AIRSUPRA, ATRICLIP LAA EXCLUSION SYSTEM, Auvelity, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, ONPATTRO, QULIPTA, Qelbree, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, VOQUEZNA, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error